Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Edoxaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 0.99 |
| ▸ | F2 | P00734 | 2/20 | 0.99 |
| ▸ | F5 | P12259 | 1/20 | 0.99 |
| ▸ | PLAT | P00750 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edoxaban SCHEMBL716662 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL16543780 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL330046 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL715737 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL1312016 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL713017 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL715418 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL2125499 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL1504007 | 0.99 | F10 (1.00) | F10F2F5PLAT | |
| Edoxaban SCHEMBL12320151 | 0.99 | F10 (1.00) | F10F2F5PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2140867-B2 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | claimed |
| EP-2140867-B1 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO CO LTD (JP) | 2017-08-30 | — | — | EP | claimed |
| US-20150342938-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO CO LTD (JP) | 2015-12-03 | — | — | US | claimed |
| US-9149532-B2 | Pharmaceutical composition | Daiichi Sanykyo Company, Limited (JP) | 2015-10-06 | — | — | US | claimed |
| US-20130337064-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-19 | — | — | US | claimed |
| US-20100081685-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | claimed |
| EP-2140867-A1 | PHARMACEUTICAL COMPOSITION | Daiichi Sankyo Company, Limited (JP) | 2010-01-06 | — | — | EP | claimed |
| EP-2140867-B2 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| EP-2540318-B1 | SUSTAINED-RELEASE SOLID PREPARATION FOR ORAL USE | DAIICHI SANKYO CO LTD (JP) | 2018-10-24 | — | — | EP | disclosed |
| EP-2742941-B1 | PHARMACEUTICAL COMPOSITION CONTAINING DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-9918975-B2 | Method for improving dissolution of anticoagulant agent | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-2140867-B1 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO CO LTD (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-2602242-B1 | PROCESS FOR PREPARING COMPOUND BY NOVEL SANDMEYER-LIKE REACTION USING NITROXIDE RADICAL COMPOUND AS REACTION CATALYST | DAIICHI SANKYO CO LTD (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | F10 9/4885F2 1/4885F5 7/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | F10 196/4885F2 4/4885F5 48/4885 |
| US-20130337064-A1 | PHARMACEUTICAL COMPOSITION | ADH1C, ADH1A, SLC5A1 | F10 495/4885F2 1010/4885F5 1390/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | F10 196/4885F2 4/4885F5 48/4885 |
| US-20150342938-A1 | PHARMACEUTICAL COMPOSITION | ADH1C, ADH1A, SLC5A1 | F10 495/4885F2 1010/4885F5 1390/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | F10 196/4885F2 4/4885F5 48/4885 |
| US-20100081685-A1 | PHARMACEUTICAL COMPOSITION | ADH1C, ADH1A, SLC5A1 | F10 495/4885F2 1010/4885F5 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.